- MEB 5: Package leaflet of pharmaceutical products
- MEB 6: Labelling of pharmaceutical products
- MEB 8: Guideline on the excipients in the label and the package leaflet of medicinal products for human use (Dutch translation)
- MEB 9: Objection procedure
- MEB 13: Nomenclature of pharmaceutical products
- MEB 14: Parallel import: marketing authorisation and maintenance
- MEB 15: Replica marketing authorisation (only applies to existing marketing authorisations)
- MEB 16: Duplex marketing authorisation
- MEB 18: Written and verbal opinion procedure for a proposed primary judgement by the MEB
- MEB 21: Statement of ‘abbreviated indications’ on OTC medicinal product packaging
- MEB 27: MEB commentary on the ‘Guideline on Summary of Product Characteristics’
- MEB 39: Policy for assigning RVG numbers
- MEB 41: MEB policy concerning marketing authorisations without Dutch translations of the product information and/or mock-ups
- MEB 42: Renewal of medicinal products for human use authorised through the national procedure
- MEB 43: Two-round assessment policy for national procedures
- MEB 44: Direct Healthcare Professional Communications (DHPCs)
- MEB 45: National implementation of additional risk minimisation measures
- MEB 47: Assessment criteria for combination packages
- MEB 48: National informed consent application
- Terms and conditions for package fee and reduced fee for copy DCP application - human products
- Question and answer document pertaining to variations for medicines for human use
- Question and answer document concerning changes not covered by the Variation Regulation 1234.2008 (as amended by Regulation 712/2012)
- Disinfectant products: Distinguishing between biocidal products and medicinal products (human and veterinary)
- List of patient-friendly terms
